Abstract 2579
Background
NSR-SCC is a rare subset of bladder tumors distinct from urothelial carcinoma (UC). Most studies that have assessed molecular biomarkers in bladder cancer have been limited to UC. We aim to characterize the genomic profile of NSR-SCC and to correlate genomic alterations with survival outcomes.
Methods
This was a retrospective study of NSR-SCC patients (pts) at Princess Margaret Cancer Centre. Patient demographics, risk factors, disease characteristics, treatment modalities, and survival outcomes were collected for eligible pts. Genomic DNA and complementary DNA were analyzed using Oncomine® V3 assay, a targeted NGS platform. Overall survival (OS) was estimated by Kaplan-Meier (log-rank). Uni- (UVA) and multi-variate (MVA) analysis (Cox-regression) was used to evaluate the impact of patient and genomic characteristics on OS.
Results
We identified 11 pts with NSR-SCC from 2002-2017, with median age 71 years (range 46-86) and 7 were male. Nine pts had muscle invasive, 1 superficial stage and 1 distant metastasis. Nine pts had radical cystectomy and LN dissection. Eight pts had pT3 or pT4 with N0 and 6 were grade 2. Median OS was 12.5 months (95 % CI 7.7- 17.2 months). Common point mutations were identified in TERT (73%), TP53 (73%), PIK3CA (27%), CREBBP (18%), FBXW7 (18%), and PTEN (18%). Amplifications were identified in EGFR (18%), FGF3 (18%), CCND1 (18%), and FGF19 (18%). Additional mutations were detected at a frequency <10%. On UVA, only bladder irritants (e.g. prior radiation, urinary catheter, infection) were associated with improved OS (HR = 0.091; p = 0.031). A limited MVA didn’t identify any significant prognostic genomic abnormalities: TP53 (HR = 2.2; 95%CI: 0.3-17; p = 0.425), TERT (HR = 1.45; 95%CI: 0.2-10.2; p = 0.70) and PIK3CA (HR = 0.46; 95%CI: 0.1- 2.0; p = 0.31).
Conclusions
In this NSR-SCC series, we identified a number of actionable genomic alterations that may be targeted with drugs. No mutation was able to define different prognostic groups. Many of these aberrations were seen in UC. Biomarker driven studies in UC should consider enrollment of NSR-SCC pts who harbor these putative mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Aaron Hansen.
Funding
Astellas.
Disclosure
A.G. Sacher: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self): Merck; Honoraria (self): Genentech-Roche. G. Kulkarni: Advisory / Consultancy: Janssen; Advisory / Consultancy: Astellas; Advisory / Consultancy: Roche; Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Ferring; Advisory / Consultancy: Sanofi. A. Zlotta: Advisory / Consultancy: Sanofi; Advisory / Consultancy: Ferring; Advisory / Consultancy: Janssen. A.R. Hansen: Advisory / Consultancy, Research grant / Funding (self): Genentech; Advisory / Consultancy, Research grant / Funding (self): Roche; Advisory / Consultancy, Research grant / Funding (self): Merck; Advisory / Consultancy, Research grant / Funding (self): GSK; Advisory / Consultancy, Research grant / Funding (self): Bristol-Myers; Advisory / Consultancy, Research grant / Funding (self): Squibb; Advisory / Consultancy, Research grant / Funding (self): Novartis; Advisory / Consultancy, Research grant / Funding (self): Boston Biomedical; Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
3988 - Basal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial.
Presenter: Sara Santagata
Session: Poster Display session 3
Resources:
Abstract
2142 - Low NK Cell Abundance Correlates with High Expression of PD-1 in CD8+ T Cells
Presenter: Moon Hee Lee
Session: Poster Display session 3
Resources:
Abstract
5501 - Tobacco smoking is associated with the immune suppressive microenvironment in head and neck squamous cell carcinoma (HNSCC)
Presenter: Christine Chung
Session: Poster Display session 3
Resources:
Abstract
5726 - Evaluation of Antibody-Dependent Cell Cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy.
Presenter: Francesca Sparano
Session: Poster Display session 3
Resources:
Abstract
2534 - Radiomic Signatures for Identification of Tumors Sensitive to Nivolumab or Docetaxel in Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Presenter: Laurent Dercle
Session: Poster Display session 3
Resources:
Abstract
3366 - Analysis of gut microbiota in advanced non-small cell lung cancer (NSCLC) patients treated with immune-checkpoints blockers
Presenter: FEIYU ZHANG
Session: Poster Display session 3
Resources:
Abstract
2089 - Pathogenesis of Myocarditis Following Treatment with Immune Checkpoint Inhibitors in a Cynomolgus Monkey Model
Presenter: Changhua Ji
Session: Poster Display session 3
Resources:
Abstract
4463 - Effects of dietary restriction in cancer patients receiving irinotecan
Presenter: Ruben Van Eerden
Session: Poster Display session 3
Resources:
Abstract
4841 - Investigating the Link between Burn Injury and Tumorigenesis
Presenter: Lucy Barrett
Session: Poster Display session 3
Resources:
Abstract
4619 - Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in male breast cancer patients
Presenter: Joanna Huszno
Session: Poster Display session 3
Resources:
Abstract